These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23646111)

  • 1. Neurocognitive function in HIV infected patients on antiretroviral therapy.
    Winston A; Arenas-Pinto A; Stöhr W; Fisher M; Orkin CM; Aderogba K; De Burgh-Thomas A; O'Farrell N; Lacey CJ; Leen C; Dunn D; Paton NI;
    PLoS One; 2013; 8(4):e61949. PubMed ID: 23646111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.
    Garvey L; Surendrakumar V; Winston A
    HIV Clin Trials; 2011; 12(6):333-8. PubMed ID: 22189152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.
    Arenas-Pinto A; Stöhr W; Jäger HR; Haddow L; Clarke A; Johnson M; Chen F; Winston A; Godi C; Thust S; Trombin R; Cairns J; Solanky BS; Golay X; Paton NI;
    Clin Infect Dis; 2016 Jul; 63(2):257-64. PubMed ID: 27143662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.
    Tozzi V; Balestra P; Salvatori MF; Vlassi C; Liuzzi G; Giancola ML; Giulianelli M; Narciso P; Antinori A
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):56-63. PubMed ID: 19731418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals.
    Smith PR; Sarner L; Murphy M; James B; Thomas JM; Skinner CJ; Aitken C
    J Clin Virol; 2003 Jan; 26(1):101-7. PubMed ID: 12589840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
    Robertson K; Maruff P; Ross LL; Wohl D; Small CB; Edelstein H; Shaefer MS
    J Neurovirol; 2019 Feb; 25(1):22-31. PubMed ID: 30298202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study.
    van den Dries LWJ; Wagener MN; Jiskoot LC; Visser M; Robertson KR; Adriani KS; van Gorp ECM
    AIDS Patient Care STDS; 2017 Aug; 31(8):329-334. PubMed ID: 28753395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.
    Kelly CM; van Oosterhout JJ; Ngwalo C; Stewart RC; Benjamin L; Robertson KR; Khoo S; Allain TJ; Solomon T
    PLoS One; 2014; 9(6):e98962. PubMed ID: 24915530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive Function in Young Persons With and Without Perinatal HIV in the AALPHI Cohort in England: Role of Non-HIV-Related Factors.
    Judd A; Le Prevost M; Melvin D; Arenas-Pinto A; Parrott F; Winston A; Foster C; Sturgeon K; Rowson K; Gibb DM;
    Clin Infect Dis; 2016 Nov; 63(10):1380-1387. PubMed ID: 27581764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive and quality of life study in perinatally HIV-infected young people and their peers. NeuroCoRISpeS study.
    García-Navarro C; Martín-Bejarano M; Jimenez de Ory S; Zamora B; Ruiz-Saez B; Velo C; Cuéllar-Flores I; Garcia Lopez-Hortelano M; Guillen-Martin S; Navarro-Gómez ML; Ramos JT; González-Tomé MI;
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Nov; 38(9):417-424. PubMed ID: 32113706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues.
    Clarke A; Johanssen V; Gerstoft J; Clotet B; Ripamonti D; Murungi A; Bicer C; Hadacek MB; Moecklinghoff C
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19526. PubMed ID: 25394035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. African ethnicity can influence immunological responses to highly active antiretroviral therapy and immunological success at 48 months: a retrospective pilot study.
    Guillaume C; N'Guyen Y; Brodard V; Bani-Sadr F; Jaussaud R; Andreoletti L
    Int J Infect Dis; 2013 Dec; 17(12):e1259-62. PubMed ID: 24139227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy.
    Cervero M; Agud JL; Torres R; García-Lacalle C; Alcázar V; Jusdado JJ; Moreno S
    HIV Med; 2013 Oct; 14(9):556-62. PubMed ID: 23738846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.
    Winston A; Stöhr W; Antinori A; Arenas-Pinto A; Llibre JM; Amieva H; Cabié A; Williams I; Di Perri G; Tellez MJ; Rockstroh J; Babiker A; Pozniak A; Raffi F; Richert L;
    HIV Med; 2016 Jun; 17(6):471-8. PubMed ID: 26611175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.
    Wright EJ; Grund B; Robertson K; Brew BJ; Roediger M; Bain MP; Drummond F; Vjecha MJ; Hoy J; Miller C; Penalva de Oliveira AC; Pumpradit W; Shlay JC; El-Sadr W; Price RW;
    Neurology; 2010 Sep; 75(10):864-73. PubMed ID: 20702792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive Impairment in Well-Controlled HIV-Infected Patients: A Cross-Sectional Study.
    Portilla I; Reus S; León R; van-der Hofstadt C; Sánchez J; López N; Boix V; Merino E; Portilla J
    AIDS Res Hum Retroviruses; 2019 Jul; 35(7):634-641. PubMed ID: 30880401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive function in HIV-infected patients with low weight and weight loss.
    Dolan S; Montagno A; Wilkie S; Aliabadi N; Sullivan M; Zahka N; Sherman JC; Grinspoon S
    J Acquir Immune Defic Syndr; 2003 Oct; 34(2):155-64. PubMed ID: 14526204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Wright EJ; Grund B; Cysique LA; Robertson KR; Brew BJ; Collins G; Shlay JC; Winston A; Read TR; Price RW;
    HIV Med; 2015 Apr; 16 Suppl 1():97-108. PubMed ID: 25711328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.